MedTrace Logo

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

NCT07629778 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-06-23

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.

Conditions

Interventions

DRUG

HL-300

Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.

DRUG

Placebo

BID, day 7.

DRUG

HL-300

Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.

DRUG

HL-300

Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.

Sponsors & Collaborators

  • Hangzhou Highlightll Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Wu Liming NA, Doctor of Medicine · First People's Hospital of Hangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629778 on ClinicalTrials.gov